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Practical applications of the present study 
Plasma levels of linoleic acid were not related to patient or graft survival after renal transplantation. Our 









Objective: The major n-6 polyunsaturated fatty acids linoleic acid (LA) and arachidonic acid (AA) play a 
role in inflammation and glucose metabolism, which could influence patient and renal transplant survival.  
 
Design: Single center cohort study. 
 
Setting and study subjects: Cohort of 1988 Norwegian renal transplant recipients.  
 
Methods and main outcome measures: We assessed associations between plasma levels of LA and AA at 
baseline, measured by gas chromatography, and patient and graft survival, as well as inflammation and 
cardiovascular risk markers. 
 
Results: During follow-up (median of 9.6 years), 595 patients died and 805 renal transplants were lost, 
either due to recipient death or graft failure. In multivariable survival analysis, we found no associations 
with mortality for plasma levels of LA (HR 0.99, 95% CI 0.96-1.01) or AA (HR 1.01, 95% CI 0.96-1.06). 
No associations were found for either cardiovascular mortality, overall graft loss or death censored graft 
loss. Levels of plasma glucose, pro-glycemic marker chemerin and pro-inflammatory marker growth 
differentiation factor 15 were inversely associated with plasma LA level and positively associated with 
plasma AA levels in multivariable analysis. 
 
Conclusions: We found no associations between plasma levels of LA or AA and patient or graft survival. 
Plasma levels of LA and pro-glycemic indices were inversely associated, signaling a possible beneficial 






Linoleic acid (LA) and arachidonic acid (AA) are the major n-6 polyunsaturated fatty acids (PUFAs) in the 
diet.1 While LA is an essential fatty acid (FA) and thus entirely dependent on dietary intake, AA can in 
addition be obtained by endogenous metabolism of LA. LA is mainly found in nuts and vegetable oils and 
AA in eggs, poultry and meat.2 3 Reports from other patient populations suggest that LA may prevent 
development of type 2 diabetes mellitus (T2DM) 4 possibly through beneficial effects on insulin sensitivity.5 
The mechanism is not completely revealed but the anti-inflammatory properties of LA is likely involved. In 
contrast, AA and its metabolites also have pro-inflammatory and pro-glycemic effects6, and both 
hyperglycemia and inflammation are independent risk factors for cardiovascular (CV) disease, which is the 
leading cause of death in renal transplantation recipients (RTRs).7 
 
To our knowledge, no data exist on the long-term impact of n-6 PUFA consumption in patients undergoing 
organ transplantation and no previous study has assessed associations between plasma n-6 PUFA levels and 
inflammatory or CV risk markers in a renal transplant cohort.  
 
The aim of the present study was to assess whether plasma levels of LA and AA were associated with 
mortality and graft loss in RTRs. In addition, we assessed cross-sectional associations between plasma LA 
and AA levels and various inflammatory and CV risk markers. 
 
 
Materials and methods 
Study population and clinical data 
The study population and design have previously been described in detail.8-10 In short, 1988 out of 2345 
eligible renal transplant recipients, transplanted at Oslo University Hospital, Rikshospitalet, during 
September 1999 through October 2011, were included in the study. Patients not eligible for participation in 
the study included patients under the age of 16 years, patients transferred to their local hospitals within 10 
weeks after transplantation, and patients who suffered graft failure or died within the first 10 weeks 
following renal transplantation. The immunosuppressive protocol was based on a combination of a 
calcineurin inhibitor, prednisolone and a cell proliferation inhibitor, with some variation during the study 
period. Until 2007, the calcineurin inhibitor of choice was cyclosporine, followed by a period where the 
choice of calcineurin inhibitor (tacrolimus or cyclosporine) was based on recipient age and CV risk profile. 
Tacrolimus has been the calcineurin inhibitor of choice from 2012, but patients started on cyclosporine were 
not switched to tacrolimus. Statin became standard therapy during the study period, with a coverage from 
30% in 2000 to >70% from 2007 and onwards.  
 
The study was approved by the Regional Committees for Medical and Health Research Ethics in Norway 
and was performed in accordance with the Declaration of Helsinki. 
 
Data collection and laboratory methods 
Clinical data were obtained from medical records. The Norwegian Renal Registry, which includes all 
Norwegian patients on renal replacement therapy, provided endpoint data. Overall renal graft loss included 
both functional grafts lost due to recipient death and death censored graft loss (return to dialysis therapy or 
renal re-transplantation). At 10 weeks post-transplant, all patients underwent a uniform clinical investigation 
at the Laboratory for renal physiology at Oslo University Hospital, Rikshospitalet. Blood was sampled and 
aliquots of biobanked samples were sent to The Lipid Research Center, Aalborg University Hospital for FA 
analysis by gas chromatography as previously described.8 Individual FAs were identified and quantified as 
weight percentage (wt%) of total plasma FA. Plasma inflammation markers were analyzed at The Research 
Institute of Internal Medicine at Oslo University Hospital, Rikshospitalet and at The Research Laboratory, 
Nordland Hospital, Bodø using enzyme immunoassay and multiplex cytokines assay as appropriate.9 In non-
diabetic patients, fasting plasma glucose (fPG) was measured and 2-hours post-challenge plasma glucose 
(2hPG) was obtained during a standard OGTT. Inflammatory markers were measured in patients 





The main statistical approach was survival analysis, using Cox proportional hazard regression with all-cause 
mortality and overall graft loss as outcomes, and proportional hazard regression model for the 
subdistribution of competing risks as described by Fine and Grey 11 for outcomes CV mortality and death 
censored graft loss. We estimated crude, age and gender adjusted and multivariable adjusted hazard ratios 
(HR) of reaching mortality and graft loss end-points. Proportional hazard assumptions were checked by 
inspection of the log-log survival time plots and by a formal hypothesis test (Schoenfeld residuals). Cross-
sectional associations between plasma phospholipid levels of LA and AA and inflammatory biomarkers and 
CV risk markers at 10 weeks post-transplant were assessed by age and gender adjusted and multivariable 
adjusted linear regression. Candidate variables were included in final regression models in a stepwise 
forward manner (inclusion criteria of p<0.10). Plasma levels of either LA or AA were forced into the final 
model. Statins were paused during the first 3 months after renal transplantation and thus do not influence 
cross-sectional associations. Only patients without overt DM underwent measurements of fPG and 2hPG. 
Associations between plasma phospholipid LA and AA levels and various inflammatory and CV risk 
markers are presented as unstandardized regression coefficient (Unstd. β-coeff.), corresponding 95% 
confidence intervals (CI) and standardized regression coefficient (Std. β-coeff.). Due to non-normal 
distribution, dialysis vintage and inflammatory biomarkers were logarithmically transformed before they 
were entered as variables in linear regression analyses. Thus, for inflammatory biomarkers, the presented 
Unstd. β-coeff. and corresponding 95% CI represents the anti-logarithm of obtained results. SPSS® version 
24.0 (IBM, NY, US) and STATA® version 14.0 (Stata Corp, College Station, Texas, US) were used for the 





Levels of AA and LA in plasma were inversely correlated (Pearsons’r = -0.30).  As can be seen in Table 1, 
multiple baseline characteristics were associated with AA and LA levels. In particular, patients with high 
LA and AA were younger, male, had better renal function, used different immunosuppressive agents, had a 
higher prevalence of DM at the time of transplantation and a different biochemical profile including lower 
total cholesterol. Patients with high LA had lower body mass index (BMI) while patients with high AA had 
higher BMI.  
 
During follow-up (19 906 person-years with a median follow-up of 9.6 years) there were 595 deaths (30%), 
including 225 deaths from cardiovascular causes. A total of 805 renal grafts were lost, either due to recipient 
death (n=497) or death censored graft loss (n=308). 
 
Linoleic acid 
In univariate analysis, we found significant inverse associations between plasma LA levels and overall graft 
loss and all-cause and CV mortality, but not death censored graft loss (Table 2). After adjustment for 
traditional and transplant specific risk factors, no significant associations were found between plasma LA 
levels and mortality or graft loss end-points (Table 2). Subgroup analyses revealed no interactions between 
LA levels and DM or indices of glucose metabolism on long-term outcomes. 
 
In a multivariable linear regression analysis, plasma levels of LA were inversely associated with fPG and 
2hPG and positively associated with plasma high-density lipoprotein (HDL) cholesterol levels (Table 3). 
Plasma LA levels were negatively associated with levels of growth differential factor 15 (GDF-15) and 
chemerin (Table 4).  
 
Arachidonic acid 
Plasma levels of AA were not associated with all-cause mortality (crude HR 0.98 [0.93-1.02], multivariate 
HR 1.01 [0.96-1.06]) or overall graft loss (crude HR 1.00 [0.96-1.04], multivariate HR 1.01 [0.96-1.05]). 
Multivariable linear regression revealed that plasma AA was negatively associated with plasma HDL 
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cholesterol levels and positively associated with fPG and 2hPG (Table 3). Further, regression analysis 




Plasma levels of LA and AA levels were not associated with either patient or graft survival after adjustment 
for confounders. We found negative associations between plasma LA levels and pro-glycemic and pro-
inflammatory indices, while positive associations with the same markers were found for plasma AA levels.  
 
Patient and graft survival 
High levels of LA and AA were often found in young RTRs, which inevitably will infer confounding, and 
crude survival data should be interpreted with caution. After adjustment for multiple confounders, we found 
no significant associations between plasma levels of LA or AA, mortality and graft loss, suggesting no 
survival benefit from enriching the diet with LA, despite possible beneficial anti-glycemic and anti-
inflammatory effects. Much of the concern regarding n-6 PUFA consumption is related to unfavorable 
metabolic and inflammatory effects of eicosanoid deriving from AA. The findings of this study do not 
support this concern, as no unfavorable association with long-term outcomes was found in patients with high 
plasma levels of AA. 
 
Inflammation, lipid and glucose metabolism  
We found that higher plasma levels of LA are associated with lower fPG and 2hPG, even after adjustment 
for potential confounders. A similar cross-sectional correlation between plasma LA and glucose levels were 
found in a recent population-based study from the Netherlands.12 In the present study, plasma LA levels 
showed a particularly strong negative association with chemerin, a cytokine involved in adipocyte 
differentiation, glucose and lipid metabolism and immune regulation.13 14 Chemerin levels normalize early 
after renal transplantation and do not reflect pre-transplant levels at 10 weeks post-transplant.15 Since both 
pre- and post-transplantation DM is frequent and associated with increased mortality,16 the potential anti-
glycemic properties of LA would be of particular interest in an organ transplant cohort.  
 
In humans, LA has been shown to lower low-density lipoprotein (LDL) cholesterol, and higher PUFA levels 
are associated with a reduced ratio of total to HDL cholesterol.17 Reports from cohort studies in the general 
population indicate that LA consumption lower the risk of CV disease.18 19 We found a positive association 
between plasma LA levels and HDL cholesterol levels in this cohort, but no association with LDL 
cholesterol. 
 
Higher plasma LA levels were also associated with lower GDF-15 levels, a transforming growth factor-beta 
superfamily stress-response cytokine, associated with DM, cancer, CV disease and mortality.20 In humans, 
short-term high dose LA consumption reduced circulating pro-inflammatory cytokine levels.21 However, we 
did not detect an association between plasma LA levels and markers of tumor necrosis factor pathway 
activation. For AA, there is firm evidence for a pro-inflammatory effect,6 and we found a positive 
association with GDF-15 levels. 
 
We have previously reported that higher plasma levels of LA were associated with improved renal graft 
function during the first year after transplantation.22 However, we did not find an association between 
plasma LA levels and death censored graft loss in this cohort. 
 
Strengths and limitations  
In addition to the observational design, there are several limitations in the present study. We lack data on 
dietary habits to adjust for the full matrix of nutrients. There might be residual confounding from a 
potentially healthier lifestyle associated with higher levels of LA. Plasma FA composition at 10 weeks post-
transplant may not reflect long-term FA profile and this concern extends to plasma inflammatory biomarkers 
and CV risk markers, also analyzed at the same point of time. Circulating inflammatory cytokines may stem 
from sources outside the renal graft and we lack data on urinary inflammation markers to check for 
7 
 
consistency. Our findings may not apply to other patient populations with different dietary habits. This study 
also has substantial strengths, including a large and well-defined population, uniform clinical procedures, a 
long follow-up period, few missing data and adjustment for several traditional and transplant-specific 




In this renal transplant cohort, we found no associations between plasma levels of LA and survival. Plasma 
LA levels were negatively associated with fPG, 2hPG and chemerin, while plasma AA level showed 
positive associations with these glycemic indices, suggesting an anti-glycemic effect of LA consumption and 
a pro-glycemic effect of AA consumption. Inverse associations with GDF-15 signals that LA might possess 




1. Burr GO, Burr, M. M. A New Deficiency Disease Produced by the Rigid Exclusion of Fat from the Diet. J Biol 
Chem 1929;82:345-67. 
2. Whelan J, Fritsche K. Linoleic acid. Adv Nutr 2013;4(3):311-2.  
3. Schwingshackl L, Schwedhelm C, Hoffmann G, et al. Food groups and risk of all-cause mortality: a systematic 
review and meta-analysis of prospective studies. Am J Clin Nutr 2017;105(6):1462-73.  
4. Forouhi NG, Imamura F. Association of Plasma Phospholipid n-3 and n-6 Polyunsaturated Fatty Acids with Type 2 
Diabetes: The EPIC-InterAct Case-Cohort Study. PLoS Med 2016;13(7):e1002094. 
5. Imamura F, Micha R, Wu JH, et al. Effects of Saturated Fat, Polyunsaturated Fat, Monounsaturated Fat, and 
Carbohydrate on Glucose-Insulin Homeostasis: A Systematic Review and Meta-analysis of Randomised 
Controlled Feeding Trials. PLoS Med 2016;13(7):e1002087 
6. Calder PC. Dietary arachidonic acid: harmful, harmless or helpful? Br J Nutr 2007;98(3):451-3.  
7. Israni AK, Snyder JJ, Skeans MA, et al. Predicting coronary heart disease after kidney transplantation: Patient 
Outcomes in Renal Transplantation (PORT) Study. Am J Transplant 2010;10(2):338-53.  
8. Eide IA, Jenssen T, Hartmann A, et al. The association between marine n-3 polyunsaturated fatty acid levels and 
survival after renal transplantation. Clin J Am Soc Nephrol 2015;10(7):1246-56.  
9. Eide IA, Asberg A, Svensson M, et al. Plasma Levels of Marine n-3 Fatty Acids Are Inversely Correlated With 
Proinflammatory Markers sTNFR1 and IL-6 in Renal Transplant Recipients. J Ren Nutr 2016; 27:161-168. 
10. Eide IA, Dahle DO, Svensson M, et al. Plasma levels of marine n-3 fatty acids and cardiovascular risk markers in 
renal transplant recipients. Eur J Clin Nutr 2016; 70:824-830. 
11. JP F. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 
1999;94:496–509. 
12. Cabout M, Alssema M, Nijpels G, et al. Circulating linoleic acid and alpha-linolenic acid and glucose metabolism: 
the Hoorn Study. Eur J Nutr 2016 (Epud ahead of print). 
13. Bobbert T, Schwarz F, Fischer-Rosinsky A, et al. Chemerin and prediction of Diabetes mellitus type 2. Clin 
Endocrinol 2015;82(6):838-43. 
14. Gu P, Jiang W, Lu B, et al. Chemerin is associated with inflammatory markers and metabolic syndrome 
phenotypes in hypertension patients. Clin Exp Hypertens 2014;36(5):326-32. 
15. Rutkowski P, Sledzinski T, Zielinska H, et al. Decrease of serum chemerin concentration in patients with end stage 
renal disease after successful kidney transplantation. Regul Pept 2012;173(1-3):55-9.  
16. Eide IA, Halden TA, Hartmann A, et al. Mortality risk in post-transplantation diabetes mellitus based on glucose 
and HbA1c diagnostic criteria. Transplant Int 2016;29(5):568-78.  
17. Harris WS, Mozaffarian D, Rimm E, et al. Omega-6 fatty acids and risk for cardiovascular disease: a science 
advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical 
Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention. 
Circulation 2009;119(6):902-7.  
18. Cho BH, Dokko RC, Chung BH. Oleic, linoleic and linolenic acids enhance receptor-mediated uptake of low 
density lipoproteins in Hep-G2 cells. J Nutr Biochem 2002;13(6):330-36. 
19. Sato M, Yoshida S, Nagao K, et al. Superiority of dietary safflower oil over olive oil in lowering serum cholesterol 
and increasing hepatic mRnas for the LDL receptor and cholesterol 7alpha-hydroxylase in exogenously 
hypercholesterolemic (exHC) rats. Biosci Biotechnol Biochem 2000;64(6):1111-7.  
8 
 
20. Wollert KC, Kempf T, Wallentin L. Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. 
Clin Chem 2017;63(1):140-51.  
21. Schmid A, Bala M, Leszczak S, et al. Pro-inflammatory chemokines CCL2, chemerin, IP-10 and RANTES in 
human serum during an oral lipid tolerance test. Cytokine 2016;80:56-63.  
22. Eide IA, Dorje C, Svensson M, et al. Development of Kidney Transplant Fibrosis Is Inversely Associated With 





Table 1. Baseline characteristics of study participants according to plasma levels of n-6  
polyunsaturated fatty acid. 







levels p Low levels 
High 
levels p 
Level (wt%)  < 25.00 ≥ 25.00  < 7.75 ≥ 7.75  
Number of patients 1988 1049 939  995 993  
Recipient age, years 51 (14) 54 (14) 49(15 <0.001 53 (14) 50 (14) <0.001 
Donor age, years 47 (16) 49 (16) 45 (16) <0.001 48 (16) 47 (16) 0.28 
Gender (Male), % 67 65 70 0.01 65 70 0.03 
eGFR, ml/min x 1.73m2 56 (18) 55 (19) 58 (19) 0.006  55 (18) 59 (19) <0.001 
Tacrolimus, % 21 17 27 <0.001 18 25 <0.001 
Cyclosporin, % 74 79 70 <0.001 78 70 <0.001 
Atherosclerotic disease, % 22 24 21 0.25 20 25 0.02 
Diabetes mellitus, % 18 15 22 <0.001 15 21 <0.001 
Current smoker, % 20 18 22 0.04 21 19 0.4 
Number of antihypertensive drugs 
     None or one, % 
     Two or three, % 




















Body mass index, kg/m2 24 (3.8) 25 (4.0) 24 (3.6) <0.001 24 (3.7) 25 (4.0) <0.001 




4.0 (0.3) <0.001 
Fasting plasma glucose, mg/dL 101 (36) 99 (35) 103 (38) 0.02 101 (38) 101 (35) 0.94 
Total cholesterol, mg/dL 244 (58) 247 (60) 240 (56) 0.007 249 (56) 239 (60) <0.001 
LDL cholesterol, mg/dL 
 
158 (65) 161 (82) 154 (48) 0.02 160 (49) 155 (84) 0.14 
HDL cholesterol, mg/dL 
  
59 (18) 58 (18) 60 (19) 0.10 61 (19) 57 (18) <0.001 
Dialysis vintage, months 9 (0-19) 9 (0-19) 8 (0-19) 0.14 8 (0-18) 10 (1-21) 0.01 
Preemptive transplantation, % 25 25 26 0.41 26 24 0.27 
First renal transplant, % 90 91 89 0.10 90 90 0.95 
Living donor transplantation, % 31 31 32 0.47 34 29 0.03 
Number of human leucocyte 
antigen DR mismatches 
     None, % 
     One, % 





















Baseline characteristics of the study population according to levels of linoleic acid and arachidonic acid in 
weight percentage (wt%) of total plasma phospholipid fatty acids. Results are presented as proportions for 
categorical data, median (interquartile range) for dialysis vintage and mean (standard deviations) for other 
continuous data. Arbitrary cut-off values close to the median value of linoleic and arachidonic acid were 
used to define groups. Differences between groups were evaluated using Chi-square for categorical data, 





Table 2. Estimated mortality and graft loss risk according to plasma levels of linoleic acid 
 All-cause mortality Cardiovascular mortality 
Model HR 95% CI P SHR 95% CI p 
Crude 0.94 (0.91, 0.96) <0.001 0.95 (0.92, 0.99) 0.02 
Adjustment for recipient age and gender 0.99 (0.98, 1.01) 0.47 0.99 (0.95, 1.04) 0.79 
Multivariable adjustment  0.99 (0.96, 1.01) 0.28 0.99 (0.95, 1.04) 0.79 
 Overall graft loss Death censored graft loss 
Model HR 95% CI p SHR 95% CI p 
Crude 0.96 (0.94, 0.98) <0.001 1.01 (0.98, 1.05) 0.44 
Adjustment for recipient age and gender 0.99 (0.97, 1.01) 0.25 0.99 (0.96, 1.02) 0.54 
Multivariable adjustment  0.99 (0.97, 1.01) 0.26 0.99 (0.96, 1.03) 0.81 
 
Estimated relative risk of reaching all-cause mortality and overall graft loss end-points according to linoleic 
acid levels using multivariate Cox proportional hazard regression and relative risk of reaching death 
censored graft loss and cardiovascular mortality end-points using multivariable subdistributional hazard 
regression adjusting for the competing risks of recipient death (death censored graft loss) or death from non-
cardiovascular causes (cardiovascular mortality).  
Candidate variables in multivariable survival analysis registered at time of transplantation: Recipient age 
and gender, donor age, transplant era (date of transplantation prior to or after 1st January 2007), 
atherosclerotic disease (coronary artery, cerebrovascular and/or peripheral vascular disease), diabetes 
mellitus, smoking status (current smoker, former smoker or life-long non-smoker), dialysis vintage (time in 
dialysis prior to kidney transplantation), preemptive transplantation (no dialysis therapy before kidney 
transplantation), first or previous renal transplant, donor status (living or deceased) and number of human 
leukocyte antigen DR mismatches. Candidate variables registered at 10 weeks post-transplant: Choice of 
calcineurin inhibitor, body mass index, plasma cholesterol, serum albumin, estimated glomerular filtration 





Table 3. Associations between plasma levels of linoleic acid (panel A) and arachidonic acid (Panel B) 
and cardiovascular risk markers in renal transplant recipients  
 
Panel A. Linoleic acid 
 
                                    Age and gender adjusted linear regression analysis 
Cardiovascular risk markers n Unstd. β-coeff. (95% CI) Std. β-coeff. p R2 
Resting heart rate, bpm  739 0.32 (0.04, 0.60) 0.09 0.02 0.02 
Systolic blood pressure, mmHg  741 0.08 (-0.30, 0.46) 0.02 0.67 0.14 
Diastolic blood pressure, mmHg  741 -0.07 (-0.32, 0.18) -0.02 0.59 0.04 
Pulse wave velocity, m/sec  757 0.04 (-0.02, 0.10) 0.04 0.20 0.31 
Triglycerides, mg/dL  1978 -1.29 (-2.81, 0.22) -0.04 0.09 0.01 
HDL cholesterol, mg/dL  1982 0.50 (0.25, 0.75) 0.09 <0.001 0.07 
LDL cholesterol, mg/dL  1961 0.02 (-0.91, 0.96) 0.01 0.96 0.02 
Fasting plasma glucose, mg/dL  1641 -0.27 (-0.52, -0.03) -0.05 0.03 0.04 
2 hr post-challenge plasma glucose, mg/dL 1637 -0.84 (-1.48, -0.19) -0.06 0.01 0.06 
 
                 Multivariable linear regression analysis 
Cardiovascular risk markers n      Unstd. β-coeff. (95% CI) Std. β-coeff. p R2 
Resting heart rate, bpm  709 0.11 (-0.16, 0.39) 0.03 0.42 0.10 
Systolic blood pressure, mmHg  711 0.22 (-0.15, 0.59) 0.04 0.24 0.21 
Diastolic blood pressure, mmHg  711 0.11 (-0.14, 0.36) 0.03 0.38 0.13 
Pulse wave velocity, m/sec  727 0.01 (-0.05, 0.07) 0.01 0.77 0.39 
Triglycerides, mg/dL  1948 -0.51 (-2.03, 1.02) -0.02 0.52 0.07 
HDL cholesterol, mg/dL  1952 0.42 (0.18, 0.67) 0.08 0.001 0.14 
LDL cholesterol, mg/dL  1931 0.59 (-0.37, 1.56) 0.03 0.23 0.06 
Fasting plasma glucose, mg/dL  1611 -0.31 (-0.54, -0.07) -0.06 0.01 0.15 
2 hr post-challenge plasma glucose, mg/dL 1607 -0.71 (1.36, -0.06) -0.05 0.03 0.10 
 
Panel B. Arachidonic acid 
                                     Age and gender adjusted linear regression analysis  
  
Cardiovascular risk markers n Unstd. β-coeff. (95% CI) Std. β-coeff. p R2  
Resting heart rate, bpm  739 0.25 (-0.24, 0.76) 0.04 0.32 0.02  
Systolic blood pressure, mmHg  741 -0.01 (-0.69, 0.68) -0.01 0.99 0.14  
Diastolic blood pressure, mmHg  741 -0.41 (-0.87, 0.05) -0.06 0.08 0.04  
Pulse wave velocity, m/sec  757 0.14 (0.03, 0.26) 0.08 0.01 0.32  
Triglycerides, mg/dL  1978 1.85 (-1.06, 4.75) 0.03 0.21 0.01  
HDL cholesterol, mg/dL  1982 -1.34 (-1.81, -0.86) -0.12 <0.001 0.07  
LDL cholesterol, mg/dL  1961 -1.33 (-3.13, 0.46) -0.03 0.15 0.02  
Fasting plasma glucose, mg/dL  1641 1.31 (0.84, 1.77) 0.13 <0.001 0.05  
2 hr post-challenge plasma glucose, g/dL 1637 2.76 (1.52, 4.00) 0.11 <0.001 0.07  
 
                     Multivariable linear regression analysis 
 
Cardiovascular risk markers n Unstd. β-coeff. (95% CI) Std. β-coeff. p R2  
Resting heart rate, bpm  709 0.38 (-0.12, 0.88) 0.05 0.14 0.10  
Systolic blood pressure, mmHg  711 -0.32 (-1.01, 0.35) -0.03 0.35 0.21  
Diastolic blood pressure, mmHg  711 -0.30 (-0.75, 0.15) -0.05 0.19 0.13  
Pulse wave velocity, m/sec  727 0.10 (-0.02, 0.21) 0.05 0.09 0.39  
Triglycerides, mg/dL  1948 -0.31 (-3.28, 2.65) -0.01 0.84 0.07  
HDL cholesterol, mg/dL  1952 -1.04 (-1.52, -0.56) -0.09 <0.001 0.14  
LDL cholesterol, mg/dL  1931 -1.62 (-3.48, 0.23) -0.04 0.09 0.06  
Fasting plasma glucose, mg/dL  1611 0.97 (0.51, 1.43) 0.10 <0.001 0.16  
2 hr post-challenge plasma glucose, g/dL 1607 1.89 (0.62, 3.17) 0.07 0.004 0.11  
 
Age- and gender adjusted and multivariable linear regression. Regression coefficients and adjusted 
explained variance (R2) for the final model are presented. Candidate variables (p<0.10 for inclusion) are 




Table 4. Associations between plasma levels of linoleic acid (panel A) and arachidonic acid (Panel B) 
and inflammatory markers in renal transplant recipients 
 
Panel A. Linoleic acid 
 
                          Age and gender adjusted linear regression analysis 
Inflammatory markers   n               Unstd. β-coeff. (95% CI) Std. β-coeff. p R2 
GDF15, ng/L 838 0.99 (0.98, 1.00) -0.05 0.10 0.23 
PTX3, ng/mL 838 0.00 (0.98, 1.00) -0.05 0.13 0.03 
sTNFR1, ng/mL  832 1.00 (0.99, 1.01) 0.001 0.97 0.06 
Chemerin, ng/mg 836 -1.42 (-2.68, -0.17) -0.08 0.03 0.04 
IL-6, ng/mL 765 1.01 (0.98, 1.04) 0.03 0.39 0.04 
IL-10, ng/mL 813 1.02 (1.00, 1.04) 0.07 0.06 0.01 
    
      Multivariable linear regression analysis 
Inflammatory markers n    
  Unstd. β-coeff. (95% 
CI) Std. β-coeff. p R2 
GDF15, ng/L 837 0.99 (0.98, 1.00) -0.09 0.001 0.43 
PTX3, ng/mL 837 0.99 (0.98, 1.00) -0.06 0.08 0.10 
sTNFR1, ng/mL 831 1.00 (0.99, 1.01) -0.02 0.50 0.32 
Chemerin, ng/mg 835 -1.44 (-2.70, -0.20) -0.08 0.02 0.08 
IL-6, ng/mL 764 1.00 (0.98, 1.03) 0.02 0.59 0.12 
IL-10, ng/mL 812 1.26 (0.99, 1.05) 0.07 0.06 0.08 
 
Panel B. Arachidonic acid 
 
                         Age and gender adjusted linear regression analysis 
Inflammatory markers   n               Unstd. β-coeff. (95% CI) Std. β-coeff. p R2 
GDF15, ng/L 838 1.03 (1.01, 1.04) 0.01 0.001 0.23 
PTX3, ng/mL 838 1.00 (0.99, 1.02) 0.02 0.61 0.03 
sTNFR1, ng/mL  832 1.01 (1.00, 1.03) 0.07 0.03 0.06 
Chemerin, ng/mg 836 3.07 (0.79, 5.40) 0.10 0.01 0.02 
IL-6, ng/mL 765 1.03 (0.98, 1.08) 0.04 0.23 0.04 
IL-10, ng/mL 813 1.02 (0.97, 1.06) 0.03 0.47 0.003 
 
     Multivariable linear regression analysis 
Inflammatory markers    n              Unstd. β-coeff. (95% CI) Std. β-coeff. p R2 
GDF15, ng/L 837 1.02 (1.01, 1.03) 0.08 0.004 0.43 
PTX3, ng/mL 837 1.01 (0.99, 1.03) 0.04 0.25 0.10 
sTNFR1, ng/mL 831 1.01 (1.00, 1.02) 0.05 0.07 0.32 
Chemerin, ng/mg 835 2.37 (0.09, 4.64) 0.07 0.04 0.08 
IL-6, ng/mL 764 1.04 (0.99, 1.09) 0.05 0.15 0.12 
IL-10, ng/mL 812 1.01 (0.97, 1.06) 0.02 0.57 0.08 
 
Age- and gender adjusted and multivariable linear regression. Regression coefficients and adjusted 
explained variance (R2) for the final model are presented. Candidate variables (p<0.10 for inclusion) are 
given in the text.   
Abbreviations: GDF15: Growth differentiation factor 15. PTX3: Pentraxin-3. sTNFR1: Soluble tumor 
necrosis factor receptor 1.  IL-6: Interleukin 6. IL-10: Interleukin 10. 
 
